Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer

NCT00912444 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

102

Enrollment

OTHER

Sponsor class

Stopped TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.

Conditions

Breast Cancer

Interventions

DRUG: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide
DRUG: Docetaxel, cyclophosphamide

Sponsor

Shanghai Jiao Tong University School of Medicine